2024

The Eurofins network expands its BioPharma Product Testing offering in the United States with the acquisition of Infinity Laboratories, Inc. – September 16, 2024

Eurofins Discovery Introduces Innovative Discovery AI SAFIRE: A New AI-Driven Platform for Drug Discovery Trained Using Proprietary Datasets – February 29, 2024

2023

Eurofins expands presence in Indian pharmaceutical market with new state-of-the-art Hyderabad campus  – January 18, 2023

2022

Eurofins Discovery Announces Acquisition of DiscoveryBioMed – July 5, 2022

Eurofins enhances its clinical and BioPharma service offering in Japan with immune repertoire analysis technology through the acquisition of Repertoire Genesis Inc. – May 31, 2022

2021

Eurofins Technologies announces the launch of RT-PCR kits for the rapid detection of the fast spreading SARS-CoV-2 variant B.1.1.529 – November 29, 2021

CRO Emmes signs new five-year service agreement with Eurofins Central Laboratory – September 30, 2021

Transplant Genomics Launches OmniGraf™, the Only Combination Biomarker Panel That Provides the Earliest Indication of Rejection in Kidney Transplant Recipients – September 27, 2021

Eurofins and Rite Aid launch an over-the-counter, FDA-authorized, at-home COVID-19 PCR test in all Rite Aid locations in the U.S. – July 9, 2021

TruGraf contracted with Humana for in-network coverage of Medicare kidney transplant patients – July 7, 2021

Eurofins opens Europe-wide COVID-19 testing centre network to facilitate summer travel – July 2, 2021

Eurofins to acquire DNA Diagnostics Center to grow genetic testing capabilities and significantly expand further into consumer testing market – June 28, 2021

Eurofins launches a new multiplex PCR assay for rapid detection of the B.1.617 “India” SARS-CoV-2 variant – June 4, 2021

Eurofins expands its global sequencing and mutation-specific PCR capabilities to detect COVID-19 Variants of Concern and of Interest – May 25, 2021

Eurofins Scientific Announces Acquisition of Beacon Discovery, Substantially Expanding Its Integrated Drug Discovery Capabilities and Expertise – February 18, 2021

Eurofins Launches New ultra-fast Extraction-free RT-PCR Method and Upgrades its RT-PCR Assay for Use with Pharynx Gargle and Saliva Sample Matrices – February 16, 2021

Eurofins Launches Quantitative Antibody Test to Measure Immune Response to COVID-19 and Vaccines – February 11, 2021

Eurofins donates 100,000 fast PCR tests to detect SARS-CoV-2 variants B.1.1.7 (ex. UK), B.1.351 (ex. South Africa) and B1.1.248 (ex. Brazil) to hospitals around the world – February 2, 2021

Eurofins launches new tests and massive capacity for detecting and monitoring new variants of SARS-CoV-2 – January 15, 2021

Eurofins Genomics launches cost-effective SARS-CoV-2 full-length viral genome sequencing services essential in the identification of viral mutations – January 6, 2021

2020

Eurofins launches COVID-19 PCR tests with at-home self-sampling options in Europe and donates sequencing capacity to identify VUI-2020-12/01 strain reported to spread faster in the UK – December 23, 2020

Eurofins U.S. Clinical Diagnostic Laboratories Partner with Insurance Providers to Cover FDA-Authorized At-Home COVID-19 Test – December 7, 2020

Eurofins providing COVID-19 analytical testing and services for Pennsylvania Long Term Care Facilities and vulnerable population citizens – August 17, 2020

Eurofins Clinical Diagnostics Launches Lower Cost Highly Accurate COVID-19 PCR Test – August 5, 2020

Eurofins Technologies launches reagents for automated extraction of genomic SARS-CoV-2 RNA from clinical swab samples – August 4, 2020

Eurofins publishes method for early detection of asymptomatic SARS-CoV-2 virus spreaders, that does not require human PCR clinical testing – July 1, 2020

Eurofins Launches Eurofins SAFER@WORK™: a Comprehensive Suite of Risk-Based COVID-19 Safety Solutions for Businesses – May 29, 202o

Eurofins Technologies launches multiplex Real-Time PCR assay for SARS-CoV-2 (coronavirus) pathogen detection – May 7, 2020

Eurofins scientists develop multiple new solutions to support the world’s fight against the COVID-19 pandemic – ramping up production to enable over 20 million patients tests per month by end May 2020 Activity shows strong resilience in Q1 2020 – April 28, 2020

Eurofins Technologies launches multiple CE-IVD marked serologic products for the detection of antibodies in patients who have been exposed to SARS-CoV-2 (COVID-19) – April 17, 2020

Eurofins Genomics launches “SARS-CoV-2 Full-length Genome Sequencing” service to support researchers globally in their fight against the COVID-19 pandemic and outbreak source tracing – April 16, 2020

Eurofins Technologies launches multiple new products for the serologic detection of antibodies in patients who have been exposed to COVID-19 – April 9, 2020

Eurofins Scientific Offers a full range of Testing services for Personal Protective Equipment (PPEs) and Medical Devices used in the fight against the COVID pandemic – April 6, 2020

Eurofins Technologies launches testing solutions for the detection of SARS-CoV-2 on environmental surfaces – March 27, 2020

Eurofins Scientific Supports Healthcare Authorities in Europe, the U.S.A. and Brazil in their Fight against the COVID-19 Pandemic with Additional Testing Options and Fast Growing Capacity – March 19, 2020

Eurofins Supports SARS-CoV-2 Analyses – March 12, 2020

Eurofins delivers strong growth again in 2019 – March 4, 2020

2019

Adial Completes Validation of Genetic Biomarker Test in Collaboration with Eurofins for Upcoming Phase 3 Trial – December 13, 2019

Eurofins reports strong organic growth (over 6%) in Q3 2019 – October 28, 2019

Transplant Genomics, Inc. Confirms TruGraf Will Receive Medicare Coverage Effective November 25, 2019 – October 11, 2019

Eurofins Expands its Transplantation Testing Footprint with the Acquisition of Transplant Genomics Inc. – June 25, 2019

Adial Pharmaceuticals Announces Collaboration Agreement with Eurofins for Genetic Biomarker Testing to Support Upcoming Phase 3 Clinical Trial for Alcohol Use Disorder – May 7, 2019

Eurofins revenues grow 27% in Q1 2019 to EUR 1,067m – April 26, 2019

NTD Eurofins Attains New York State Department of Health (NYSDOH) Approval for the newest option to its MaternalFetalScreenSM | T1 test – Y chromosome assessment – March 27, 2019

Eurofins delivers solid FY 2018 results with revenues of EUR 3,781m (+27% yoy) and adjusted EBITDA of EUR 720m (19.0% of revenues), in line with its recently upgraded objectives – March 5, 2019

2018

Eurofins expands its biopharmaceutical products testing footprint with an outsourcing agreement with Astellas in Japan – May 22, 2018

Eurofins to expand its presence in North America, the United Kingdom & Asia with the acquisition of LabCorp’s food testing and consulting business – April 30, 2018

Eurofins exceeds its recently-upgraded 2017 objectives on a strong growth momentum and raises its objectives for 2018 – March 6, 2018

Eurofins further expands its specialty clinical diagnostics footprint with the acquisition of NMDL-LCPL in the Netherlands – February 26, 2018

Eurofins Central Laboratory Expands Global Footprint with GMP Compliant Kit Packing and Distribution Facility – February 19, 2018

Eurofins expands its offering in food and feed testing with the acquisition of Craft Technologies, Inc. – January 23, 2018

2017

Eurofins announces the successful closing of the acquisition of EAG Laboratories – December 4, 2017

With 33% CAGR annual value creation since its IPO 20 years ago (over 296 times appreciation*) a study finds that Eurofins ranks first in value creation of all stocks listed in Europe since October 24, 1997**  – October 24, 2017